লোডিং...
Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells
[Image: see text] Since the histone modifying enzymes EZH2 and HDACs control a number of epigenetic-dependent carcinogenic pathways, we designed the first-in-class dual EZH2/HDAC inhibitor 5 displaying (sub)micromolar inhibition against both targets. When tested in several cancer cell lines, the hyb...
সংরক্ষণ করুন:
| প্রকাশিত: | ACS Med Chem Lett |
|---|---|
| প্রধান লেখক: | , , , , , , , , , , , , , , |
| বিন্যাস: | Artigo |
| ভাষা: | Inglês |
| প্রকাশিত: |
American Chemical
Society
2020
|
| অনলাইন ব্যবহার করুন: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7236245/ https://ncbi.nlm.nih.gov/pubmed/32435414 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.0c00014 |
| ট্যাগগুলো: |
ট্যাগ যুক্ত করুন
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!
|